Month: January 2022

Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands

01/04/2022

Two 45 μg doses and single 90 μg of protein subunit vaccine AKS-452 were generally well-tolerated and showed robust neutralizing antibody titers Primary immunogenicity endpoints were met Vaccine is shelf stable for at least 6 months at 25° C (77° F) Phase II/III trial starting in India Excerpt from the Press Release: BEVERLY, Mass.–(BUSINESS WIRE)–Akston…

Read More